Online inquiry

IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14525MR)

This product GTTS-WQ14525MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14525MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7116MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ14447MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ12691MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ15625MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ4804MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ13478MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ7692MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ2964MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANB020
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW